Rep. Maria Elvira Salazar Buys Shares of Moderna, Inc. (NASDAQ:MRNA)

Posted by Brian Himes on Sep 12th, 2026

Representative Maria Elvira Salazar (Republican-Florida) recently bought shares of Moderna, Inc. (NASDAQ:MRNA). In a filing disclosed on September 09th, the Representative disclosed that they had bought between $1,001 and $15,000 in Moderna stock on August 19th. The trade occurred in the Representative’s “UBS IRA ACCOUNT” account.

Representative Maria Elvira Salazar also recently made the following trade(s):

Sold $1,001 – $15,000 in shares of International Business Machines (NYSE:IBM) on 8/24/2026.
Sold $1,001 – $15,000 in shares of Moderna (NASDAQ:MRNA) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/19/2026.
Purchased $15,001 – $50,000 in shares of Merck & Co., Inc. (NYSE:MRK) on 8/19/2026.
Sold $15,001 – $50,000 in shares of Chubb (NYSE:CB) on 8/19/2026.
Sold $1,001 – $15,000 in shares of Qualcomm (NASDAQ:QCOM) on 8/12/2026.
Purchased $1,001 – $15,000 in shares of SpaceX (NASDAQ:SPCX) on 8/12/2026.
Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 8/7/2026.
Purchased $1,001 – $15,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.
Purchased $15,001 – $50,000 in shares of Berkshire Hathaway (NYSE:BRK.B) on 7/28/2026.

Moderna Trading Up 5.4%

Moderna stock traded up $7.35 during midday trading on Friday, reaching $143.97. The stock had a trading volume of 15,383,796 shares, compared to its average volume of 33,437,252. Moderna, Inc. has a twelve month low of $22.28 and a twelve month high of $176.66. The company has a debt-to-equity ratio of 0.09, a current ratio of 2.29 and a quick ratio of 2.18. The firm has a market cap of $57.48 billion, a price-to-earnings ratio of -18.02 and a beta of 1.10. The firm’s fifty day simple moving average is $92.35 and its two-hundred day simple moving average is $66.74.

Moderna (NASDAQ:MRNA – Get Free Report) last announced its earnings results on Friday, July 31st. The company reported ($1.97) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.03) by $0.06. Moderna had a negative net margin of 141.43% and a negative return on equity of 28.30%. The company had revenue of $145.00 million for the quarter, compared to the consensus estimate of $102.93 million. During the same period in the previous year, the business earned ($2.13) EPS. The company’s revenue was up 2.1% on a year-over-year basis. Equities analysts anticipate that Moderna, Inc. will post -6.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

MRNA has been the subject of several research analyst reports. JPMorgan Chase & Co. increased their price objective on Moderna from $40.00 to $77.00 and gave the stock an “underweight” rating in a research note on Friday, August 21st. UBS Group set a $81.00 target price on Moderna in a research note on Thursday, September 3rd. CLSA upgraded Moderna to an “outperform” rating in a report on Friday, August 28th. Wolfe Research raised shares of Moderna from an “underperform” rating to a “peer perform” rating in a research report on Tuesday, August 25th. Finally, Rothschild & Co Redburn cut shares of Moderna from a “neutral” rating to a “sell” rating and raised their price target for the stock from $40.00 to $81.00 in a report on Thursday, September 3rd. Seven research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and five have given a Sell rating to the company’s stock. Based on data from MarketBeat, Moderna currently has a consensus rating of “Hold” and a consensus target price of $76.72.

Read Our Latest Research Report on MRNA

Institutional Trading of Moderna

Hedge funds and other institutional investors have recently modified their holdings of the company. Allied Private Wealth LLC purchased a new position in Moderna in the second quarter valued at about $30,000. Archer Investment Corp acquired a new stake in shares of Moderna during the 2nd quarter valued at about $36,000. Canton Hathaway LLC acquired a new stake in shares of Moderna during the 1st quarter valued at about $31,000. Frazier Financial Advisors LLC bought a new stake in shares of Moderna in the 2nd quarter valued at approximately $45,000. Finally, Freestone Grove Partners LP bought a new stake in shares of Moderna in the 2nd quarter valued at approximately $46,000. 75.33% of the stock is currently owned by hedge funds and other institutional investors.

Moderna News Summary

Here are the key news stories impacting Moderna this week:

Positive Sentiment: Momentum and upcoming data readouts supported the stock. Moderna rallied in Friday morning trading despite limited movement among peers. UBS reportedly identified three near-term “INT” data readouts, potentially giving investors multiple upcoming catalysts to anticipate. However, the reports did not provide detailed results or confirm that any readout will be positive. Moderna Rallies 8% on 2026 Melt-Up Momentum Even While BioNTech and Merck Stay Flat Moderna Set for 3 Near-Term INT Data Readouts, UBS Says
Neutral Sentiment: Congressional trading coverage offers no clear Moderna-specific catalyst. A report discussing recent stock transactions by members of Congress included Moderna-related investor-monitoring activity, but it did not identify a material change in the company’s outlook or operations. Congressional Stock Transactions
Neutral Sentiment: Short-interest data appears unreliable. The report listed both current and prior short interest at zero and calculated a zero-day short-interest ratio, with an invalid percentage change. Therefore, it provides little useful information about short-covering or bearish positioning in Moderna.
Negative Sentiment: Industry commercialization hurdles remain a risk. Manufacturing complexity and other barriers could slow the development and commercialization of personalized mRNA cancer vaccines, highlighting longer-term execution risks for Moderna and its peers. mRNA Cancer Vaccines’ Biggest Barriers to Market

Insider Buying and Selling

In other Moderna news, insider Shannon Klinger sold 3,471 shares of the business’s stock in a transaction that occurred on Tuesday, September 1st. The shares were sold at an average price of $139.95, for a total value of $485,766.45. Following the completion of the sale, the insider directly owned 74,129 shares of the company’s stock, valued at $10,374,353.55. The trade was a 4.47% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, President Stephen Hoge sold 53,336 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $51.37, for a total transaction of $2,739,870.32. Following the transaction, the president owned 1,483,848 shares in the company, valued at approximately $76,225,271.76. This trade represents a 3.47% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 10.80% of the company’s stock.

About Representative Salazar

Maria Elvira Salazar (Republican Party) is a member of the U.S. House, representing Florida’s 27th Congressional District. She assumed office on January 3, 2021. Her current term ends on January 3, 2027.

Salazar (Republican Party) ran for re-election to the U.S. House to represent Florida’s 27th Congressional District. She won in the general election on November 5, 2024.

Maria Elvira Salazar was born in Miami, Florida, and lives in Coral Gables, Florida. Salazar earned an undergraduate degree from the University of Miami in 1983 and a graduate degree from Harvard University in 1995. Her career experience includes working as a television journalist, reporter, and news anchor.

Moderna Company Profile

(Get Free Report)

Moderna, Inc is a biotechnology company that develops messenger RNA (mRNA) medicines and vaccines. Its platform is designed to provide cells with instructions to produce proteins that may help prevent or treat infectious diseases, cancer and other medical conditions.

The company’s commercial products include Spikevax, an mRNA vaccine for COVID-19, and mRESVIA, an mRNA vaccine for respiratory syncytial virus (RSV) in older adults. Moderna also maintains a pipeline of investigational programs in areas such as seasonal influenza, cytomegalovirus, oncology and rare diseases.

Founded in 2010 and headquartered in Cambridge, Massachusetts, Moderna serves markets in the United States and internationally through regulatory approvals, commercial partnerships and distribution arrangements.